Mirati Therapeutics, Inc. posts $7.17 million revenue in quarter ended Mar 31, 2023
By USInMinutes - May 10, 2023, 01:47 AM ET
Last Updated - Jul 18, 2023, 03:32 PM EDT
Key fundamental financials- loss of $184.59 million
- Revenue of $7.17 million
Mirati Therapeutics, Inc. [MRTX] has reported $184.59 million loss for the fiscal quarter ending Mar 31, 2023.
Revenue for the quarter was $7.17 million with operating income of $193.82 million.
The Sandiego, California (CA)-based company operating in the pharmaceutical preparations sector has total shareholders equity of $862.63 million.
Also read:
This is a developing story. Click here to receive updates.
------------
NewsInMinutes, an offering of 10kInfo, Inc., brings you news on the latest regulatory filings. Subscribe to additional news alerts here.
Sponsored
Read More from Quarterly Reports
Read More from USinMinutes
Popular News
Latest News